David O'Malley, MD, The Ohio State University Comprehensive Cancer Center

Closing the discussion on advanced endometrial carcinoma, Dr David O’Malley shares his perspective on the future treatment landscape.

David O’Malley, MD, an expert on advanced endometrial carcinoma, shares additional highlights presented at SGO 2023.

David O’Malley, MD, details patient tolerance and associated adverse events with lenvatinib plus pembrolizumab for advanced endometrial carcinoma.

An expert gynecologic oncologist reviews recent updates presented at SGO 2023 from the KEYNOTE-775 trial for advanced endometrial carcinoma.

A brief review of the current treatment armamentarium for advanced endometrial carcinoma.

David O’Malley, MD, an expert gynecologic oncologist, details molecular profiling and risk stratification for patients with advanced endometrial carcinoma.

David O’Malley, MD, provides a comprehensive overview of endometrial carcinoma and treatment options for patients in this setting.

Data from the phase 3 ATHENA-MONO study indicated that maintenance rucaparib yielded progression-free survival benefit vs placebo across all subgroups in a population of patients newly diagnosed ovarian cancer, according to David O’Malley, MD.

David M. O’Malley, MD, spoke about where the future of treatment is heading for patients with endometrial cancer.

David M. O’Malley, MD, spoke about unmet needs of patients with advanced microsatellite instability–¬high or mismatch repair deficient endometrial carcinoma and the clinical benefit pembrolizumab provides.

David M. O’Malley, MD, spoke about the approval of pembrolizumab for patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient.

CancerNetwork® sat down with David O’Malley, MD, at the 2021 European Society for Medical Oncology to talk about the OReO trial and how these findings impact what’s already known about PARP inhibitors for the treatment of ovarian cancer.